DUCLOUX Ducloux

Prof. Dr. DUCLOUX Ducloux

1. CHU Besançon, Department of Nephrology, Dialysis and Renal Transplantation, Federation Hospitalo-Universitaire INCREASE, 25000 Besançon, France
+1
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2004 in Kidney International
Verified
Journal Article
Closed access
DDDUCLOUX Ducloux
DUCLOUX Ducloux
AKAmir Kazory
Amir Kazory
JCJean-Marc Chalopin
Jean-Marc Chalopin

1 June 2005 in Kidney International
Verified
Journal Article
Closed access
PDF file
DDDUCLOUX Ducloux
DUCLOUX Ducloux
MDMarina Deschamps
Marina Deschamps
MYMaria Yannaraki
Maria Yannaraki
CFChristophe Ferrand
Christophe Ferrand
JBJamal Bamoulid
Jamal Bamoulid
PTPierre Tiberghien
Pierre Tiberghien

1 December 2005 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
DDDUCLOUX Ducloux
DUCLOUX Ducloux
AKAmir Kazory
Amir Kazory
DSDominique Simula‐Faivre
Dominique Simula‐Faivre
JCJean‐Marc Chalopin
Jean‐Marc Chalopin
Metabolic syndrome (MS) and obesity participate in the pathogenesis of kidney disease. We explored the impact of MS and post-transplant weight gain on graft survival. Two hundred ninety-two renal transplant recipients (RTRs) were included in the study. Various parameters (e.g. anthropometric, biological) were measured at the time of transplantation as well as 1 year post-transplant. The proportion of patients with overweight or obesity significantly increased during the first year post-transplant (p = 0.04). Mean weight gain was 2.7 +/- 5.8 kg. Thirty patients (10.3%) lost their graft during follow-up. In multivariate analysis, patients with an increase in body mass index (BMI) of more than 5% at 1 year post-transplant had an increased risk of graft loss with (HR: 2.82 [95% CI: 1.11-7.44], p = 0.015) or without death censoring (HR: 2.31 [95% CI: 1.06-5.04], p = 0.035). Low creatinine clearance (HR: 4.72 [95% CI: 1.63-13.69], p = 0.004), high urinary protein excretion (HR: 3.21 [95% CI: 1.27-8.18], p = 0.014) and delayed graft function (DGF) (HR: 2.621 [95% CI: 1.07-6.39], p = 0.036) were also independent risk factors for graft loss. MS did not independently predict graft loss, partly due to significant interactions with low-grade inflammation. We conclude that post-transplant weight gain significantly reduces graft survival.

1 September 2021 in Kidney International
Verified
Journal Article
Closed access
DDDUCLOUX Ducloux
DUCLOUX Ducloux
MCMathilde Colladant
Mathilde Colladant
MCMelchior Chabannes
Melchior Chabannes
MYMaria Yannaraki
Maria Yannaraki
CCCécile Courivaud
Cécile Courivaud

1 May 2010 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
DDDUCLOUX Ducloux
DUCLOUX Ducloux
CCCécile Courivaud
Cécile Courivaud
JBJamal Bamoulid
Jamal Bamoulid
BVBérengère Vivet
Bérengère Vivet
ACAline Chabroux
Aline Chabroux
PSPhilippe Saas
Philippe Saas
Prolonged CD4 T cell lymphopenia after administration of polyclonal anti-thymocyte globulins increases the rate of posttransplantation morbidity, but whether impaired immune reconstitution affects survival is unknown. We studied the effect of CD4 T cell lymphopenia on survival in 302 consecutive prevalent renal transplant recipients and the role of thymic function in CD4 T cell reconstitution and posttransplantation outcomes in 100 consecutive incident renal transplant recipients. We followed the prevalent cohort for a mean duration of 92 months. Of these 302 patients, 81 (27%) had persistent CD4 T cell counts 1 year (24.1 versus 7.6%; P < 0.001). Furthermore, in Cox regression analysis, CD4 T cell lymphopenia associated with a nearly five-fold risk for death (adjusted hazard ratio [HR] 4.63; 95% confidence interval [CI] 1.91 to 10.65; P = 0.001). In the incident cohort, we estimated thymic function by T cell receptor excision circles (TRECs) per 150,000 CD3+ cells, which predicted efficient CD4 T cell reconstitution. Higher pretransplantation TREC values associated with lower risks for cancer (adjusted HR 0.39; 95% CI 0.15 to 0.97; P = 0.046) and infection (HR 0.29; 95% CI 0.11 to 0.78; P = 0.013). In summary, prolonged polyclonal anti-thymocyte globulin–induced CD4 T cell lymphopenia is an independent risk factor for death. Determination of pretransplantation thymic function may identify patients at higher risk for CD4 T cell lymphopenia and posttransplantation morbidity, including cancer and infections.

1 February 2005 in Transplantation
Verified
Journal Article
Closed access
DDDUCLOUX Ducloux
DUCLOUX Ducloux
AKAmir Kazory
Amir Kazory
JCJean-Marc Chalopin
Jean-Marc Chalopin
Posttransplant diabetes mellitus (PTDM) is a frequent complication in renal-transplant recipients (RTRs). We conducted a prospective study to assess the potential role of PTDM in the development of atherosclerotic events (AE) in RTRs. Three hundred fifty-seven consecutive RTRs were enrolled in this study. The incidence of various AE were assessed with respect to the presence of PTDM and a number of cardiovascular (CV) risk factors. The patients were followed for a mean duration of 60±14 months. Thirty-nine (11%) patients had PTDM. Fifty AE occurred in 48 (13.4%) patients. Although AE were more frequent in RTRs with PTDM compared with nondiabetic patients (33% vs. 8.8%; P=0.007), PTDM was only modestly associated with AE in the multivariate Cox regression analysis (relative risk [RR] 1.34; 95% confidence interval [CI], 1.04–2.18), mostly caused by significant interactions between PTDM and three confounding variables that were independently associated with AE: age, serum C-reactive protein (CRP) level, and serum high-density lipoprotein cholesterol concentration. Patients with high levels of homocysteine showed a significantly increased risk of AE (RR 4.67; 95% CI 1.82–15.87), as did those with high serum levels of CRP (RR 2.57; 95% CI 1.57–6.23). Our study shows a significant association between PTDM and AE. Nevertheless, a large amount of the excess risk of posttransplant diabetic RTR is explained by the coexistence of other CV risk factors. Moreover, high serum levels of CRP and hyperhomocystinemia were found to be among the nontraditional factors contributing to AE in our patients.